Genmab A/S
DUS:GE9
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
Genmab A/S
DUS:GE9
|
DK |
|
A
|
Aeterna Zentaris Inc
F:ET82
|
US |
|
E
|
Eiffage SA
F:EF3
|
FR |
|
P
|
PetroChina Co Ltd
F:PC6
|
CN |
|
N
|
NETGEAR Inc
F:NGJ
|
US |
|
Qurate Retail Inc
F:LB3C
|
US |
|
N
|
Nordstrom Inc
XMUN:NRD
|
US |
|
T
|
TransAlta Corp
F:TZ1
|
CA |
|
VEEM Ltd
OTC:VEEMF
|
AU |
|
Dishman Carbogen Amcis Ltd
NSE:DCAL
|
IN |
|
Liberty Media Corp
OTC:LLYVB
|
US |
|
T
|
thyssenkrupp nucera AG & Co KgaA
OTC:THYKF
|
DE |
|
S
|
Steel Connect Inc
F:CGOB
|
US |
|
SFC Energy AG
OTC:SSMFF
|
DE |
|
Dateline Resources Ltd
ASX:DTR
|
AU |
|
Goliath Resources Ltd
XTSX:GOT
|
CA |
Wall St Price Targets
GE9 Price Targets Summary
Genmab A/S
According to Wall Street analysts, the average 1-year price target for GE9 is 306.86 EUR with a low forecast of 177.11 EUR and a high forecast of 424.91 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is GE9's stock price target?
Price Target
306.86
EUR
According to Wall Street analysts, the average 1-year price target for GE9 is 306.86 EUR with a low forecast of 177.11 EUR and a high forecast of 424.91 EUR.
What is the Revenue forecast for Genmab A/S?
Projected CAGR
10%
Over the last 13 years, the compound annual growth rate for Revenue has been 34%. The projected CAGR for the next 8 years is 10%.
What is the Operating Income forecast for Genmab A/S?
Projected CAGR
10%
The compound annual growth rate for Operating Income over the next 8 years is 10%.
What is the Net Income forecast for Genmab A/S?
Projected CAGR
12%
The compound annual growth rate for Net Income over the next 8 years is 12%.
